Short stories

Energy tech company closes round, hospital introduces VR brain tours, Amazon bets on Houston schools, and more innovation news

Amazon has selected eight KIPP schools in Houston to received resources to create robotics programs. Courtesy of Amazon

From virtual reality-enabled brain scans to Amazon selecting Houston schools for its robotics program, the future is now with this latest batch of local innovation news.

Need more news rounded up for you? Subscribe to our daily newsletterthat sends fresh stories straight to your inboxes every morning.

OAG Analytics closes round

Luther Birdzell, founder and CEO of Houston-based OAG Analytics is on a mission to democratize data for his upstream oil and gas clients. Courtesy of OAG Analytics

OAG Analytics, which uses artificial intelligence in the oil and gas industry, has closed its second round of strategic funding in nine months from Rice Investment Group. The capital will be used to grow the company and focus on several major enhancements to their upstream AI platform, according to a news release.

The exact amount of the raise was not disclosed by OAG, but according to a Form D filing, the company expressed that it was raising $8.72 million in this round.

"Our industry is entering the next phase of the shale revolution by moving to full-field development. As such, we need the next generation of analytical capabilities to maximize capital efficiency," says Derek Rice, partner at Rice Investment Group and director at OAG, in a release. "Large-scale development optimization requires an in-depth understanding of hundreds of uncorrelated data points, which OAG provides through data management and advanced analytics to support profitable decision making. We are thrilled to partner with OAG's team, and believe our insights and experience as an operator will continue to add value to the platform."

OAG's founder and CEO, Luther Birdzell, created a way where he can give clients an easy-to-use platform to have access to data that could save oil and gas companies millions of dollars. In fact, according to the release, OAG clients have optimized over $10 billion in capital expenditures.

"RIG's trust in the OAG team and AI platform is a huge vote of confidence," says Birdzell in the release. "As a leadership team that already built and sold a highly data-driven, technology-centric oil and gas company, RIG's market insights and capital are important to our business. We look forward to continued collaboration as we accelerate our growth."

Methodist Hospital has new VR technology for brain treatment

Patients about to undergo brain surgery can use VR to see what their surgeon is about to do to their brain. Courtesy of Methodist

Houston Methodist Hospital is channeling a Magic School Bus episode with new VR technology that allows neurosurgical patients and their family members to essentially walk through their brains ahead of their surgeries.

The patient wears a virtual reality headset and gets a 360 degree view of their brain, and the neurosurgeon can walk the patient through the surgery process. According to a release from Houston Methodist, the technology is the first of its kind that combines fighter jet flight simulation with patients' anatomy scans from MRI, CT, and/or DTI processes to make a 3D model.

Eight Houston schools named in Amazon Future Engineer Robotics Grant program

Eight Houston schools will receive resources from Amazon to create a robotics team. Courtesy of Amazon

Eight Houston schools have been selected as part of Amazon Future Engineer Robotics Grant program. The program has selected 100 schools in 21 states and each will receive support to create robotics team and a $10,000 grant. These Houston schools were selected:

  • KIPP Academy MS
  • KIPP Connect HS
  • KIPP Connect Middle School
  • KIPP Generations Collegiate
  • KIPP Northeast College Preparatory
  • KIPP NEXUS MS• KIPP Polaris
  • KIPP Sunnyside HS

The Amazon Future Engineer program launched in November, and, according to a news release, is a four-part childhood-to-career program geared at teaching technology and computer science to children from underrepresented and underserved communities. Through the program, Amazon hopes to help more than 10 million students nationwide.

Mattress Firm seeks second round of "snoozeterns"

Last summer, Mattress Firm introduced its Snoozetern program, advertising as a "dream job" for college students wanting to get "paid to sleep." The program is looking for it's next employee that will learn the ins and outs of the Houston company and test and review products. Applications are open now until May 3. To apply or learn more, visit here.

Deloitte’s 2019 Technology Fast 500 Awards are now open

Houston companies can enter to win this national recognition from Deloitte. Photo via Deloite.com

Deloitte has opened its 2019 Technology Fast 500 Awards applications. The national awards program has been honoring fast-growing tech companies for 25 years. Last year, two Houston companies were ranked: Onit and symplr. The honorees are chosen based on the past three years' of fiscal-year revenue growth over a three-year period. Applications close on June 28. Click here for more.

The Kidney Cancer Association approves $1.3 million for early detection and new treatments

Applicants have until May 20 to submit for a grant from the Kidney Cancer Association. Photo via Facebook

The Kidney Cancer Association's board of directors approved $1.3 million to be dedicated to advancing early detection and new treatments for kidney cancer. Grant applications opened April 17 and close May 20. Grant recipients will be announced in the fall.

"The KCA Board of Directors is committed to providing research funding with the goal of identifying new treatments and finding new ways to prevent and manage the disease," says Christopher Wood, board president, in a news release. "With these advancements in research and a greater understanding of these cancers, we believe the outcomes of these grants will have substantive impact for kidney cancer patients."

There will be six grants are divided into two types of awards. The Advanced Discovery Awards will honor two "established investigators" $500,000 grants, and the Young Investigator Awards will give out four $75,000 grants.

Houston neuroscientist David Eagleman to discuss new book at the Hobby Center

Courtesy images

The Barbara Bush Houston Literacy Foundation, a Houston-based nonprofit, is hosting its 25th annual A Celebration of Reading event on Thursday, May 2, at The Hobby Center for the Performing Arts. The event hosts five authors, and this year, Houston neuroscientist David Eagleman is on the lineup.

Eagleman's most recent book, The Runaway Species: How Human Creativity Remakes the World, will be the topic of discussion during his presentation. Eagleman and his co-author, Anthony Brandt, seek to determine the human mind's ability and drive to create.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted